Freeline Therapeutics Holdings PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Freeline Therapeutics Holdings PLC
Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash
Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
CSL/UniQure’s Hemgenix To Enter Uncertain EU Market After Regulatory Nod
The firms’ one-time hemophilia B gene therapy has been approved in the EU just months after a US nod, but concerns remain about its prospects on a market that has seen several setbacks for other gene therapies.
Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.